Skip to content

Effect of Boron supplementation on the severity of dysmenorrhea

Effect of Boron supplementation on the severity of dysmenorrhea in female students residing in dormitories of Shaid Beheshti University of Medical sciences in 2013- 2014

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201207153226N5
Enrollment
108
Registered
2014-05-21
Start date
2014-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhoea. Primary dysmenorrhoea

Interventions

Intervention 1: Intervention group: in people with inclusion criteria To be eaten Boron supplemental, 10 mg, oral daily((2 days before mensturation to 3 first day of bieeding) during 2 cycles. pain
Treatment - Drugs
Placebo
Intervention group: in people with inclusion criteria To be eaten Boron supplemental, 10 mg, oral daily((2 days before mensturation to 3 first day of bieeding) during 2 cycles. pain intensity with S
Control group: : in people with inclusion criteria To be eaten placebo, contains 300 mg of lactose powder, oral daily (2 days before mensturation to 3 first day of bieeding) during 2 cycles. . pain i

Sponsors

Shaid Beheshti University of Medical sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: being single; age between 18 – 25 year old; girls with primary dysmenorrhea that the pain intensity as moderate to severe based Mac Gill ruler; do not suffering from chronic diseases (diabetes, hypertension, cardiac diseases, infectious diseases, liver, kidney); regular menstruation (period between 21 – 35 days); normal BMI (19.8 – 25); have not any symptoms of itching, abnormal discharge during study; not taking any medication, supplements; they should not use any herbal remedies about 3 months ago Intervention; they should not have any deplorable event such as near relatives’ death or surgical operation in recent six months. Exclusion criteria: individual's consent to continue participating in the study; pelvic known pathology(myoma, pelvic tumor, endometriosis, PID) during the study; improper use of capsules; any use of herbal drug during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of primary dysmenorrhea. Timepoint: Before the intervention, while following intervention during the 3 first day of bleeding in 2cycles. Method of measurement: Verbal Multidimentional Scoring System Questionnaire, Mac gil ruler.

Secondary

MeasureTime frame
Complications. Timepoint: Finally of bleeding days. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahrokh Dolatian

Shaid Beheshti University of Medical Sciences

mhdolatian@yahoo.com+98 21 8820 2512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026